Log in to save to my catalogue

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Ander...

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Ander...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5962379

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

About this item

Full title

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

Publisher

New York: Springer US

Journal title

Investigational new drugs, 2018-08, Vol.36 (4), p.638-646

Language

English

Formats

Publication information

Publisher

New York: Springer US

More information

Scope and Contents

Contents

Summary
Background
Immunotherapy is emerging as the cornerstone for treatment of patients with advanced cancer, but significant toxicity (immune-related adverse events [irAEs]) associated with unbridled T cell activity remains a concern.
Patients and methods
A retrospective review of the electronic medical records of 290 patients with a...

Alternative Titles

Full title

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5962379

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5962379

Other Identifiers

ISSN

0167-6997

E-ISSN

1573-0646

DOI

10.1007/s10637-017-0534-0

How to access this item